buy

Alnylam Pharmace. buy Raymond James

Alnylam Pharmace.

Start price

€180.00

/ 50%

Target price

03.08.27

Performance (%)

Price

Summary

This prediction is currently active. With a performance of , the BUY prediction by Raymond_James for Alnylam Pharmace. is trending in the right direction. This prediction currently runs until 03.08.27. The prediction end date can be changed by Raymond_James at any time. Raymond_James has 50% into this prediction

Alnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.

AI-generated

Feedback

Performance without dividends (%)

Name	1w
Alnylam Pharmace.
iShares Core DAX®
iShares Nasdaq 100
iShares Nikkei 225®
iShares S&P 500

Comments by Raymond_James for this prediction

In the thread Alnylam Pharmace. diskutieren

Prediction Buy

Perf. (%)

Target price 364.308

Change

Ends at

Alnylam Pharmaceuticals (ALNY) was upgraded by Raymond James Financial, Inc. from "outperform" to "strong-buy". They now have a $420.00 price target on the stock.

Ratings data for ALNY provided by MarketBeat

Raymond James